Cargando…
Current and Investigational Therapeutics for Fabry Disease
Fabry disease (FD) is an X-linked lysosomal storage disease caused by a deficiency in the lysosomal enzyme α-galactosidase (α-GAL). This in turn leads to the buildup of globotriaosylceramide, resulting classically in progressive kidney disease, peripheral neuropathy, early-onset cerebrovascular dise...
Autores principales: | Felis, Andrew, Whitlow, Michael, Kraus, Abigayle, Warnock, David G., Wallace, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136345/ https://www.ncbi.nlm.nih.gov/pubmed/32274449 http://dx.doi.org/10.1016/j.ekir.2019.11.013 |
Ejemplares similares
-
Current and experimental therapeutics for Fabry disease
por: Castelli, Vanessa, et al.
Publicado: (2021) -
Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013) -
Fabry disease – current data and therapeutic approaches
por: Dinu, Ilie-Robert, et al.
Publicado: (2021) -
Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016) -
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)